SEATTLE, Wa., January 6, 2017 - Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announces it has entered into an agreement with Amgen to further develop and commercialize Adaptive’s NGS-based clonoSEQ Assay to assess minimal residual disease (MRD) in patients with Acute Lymphoblastic Leukemia (ALL).
BREAKING NEWS FROM ADAPTIVE
Seattle, WA - Adaptive Biotechnologies, the pioneer of Next Generation Sequencing (NGS) of the adaptive immune system, and its collaborators will present data demonstrating how immunosequencing can inform clinical care in patients with blood cancers at the American Society of Hematology (ASH) meeting from December 6-9, 2014.
Seattle, WA – Adaptive Biotechnologies, a pioneer in leveraging Next Generation Sequencing (NGS) to profile T- and B-cell receptors, reported today that the immunoSEQ Assay was able to help identify patients with metastatic melanoma who would be most likely to respond to treatment with pembrolizumab (an anti-PD-1 therapy), according to a study published in this week’s issue of Nature.
Seattle, WA – Adaptive Biotechnologies, a pioneer in leveraging Next Generation Sequencing (NGS) to profile T- and B-cell receptors, today launched a research use only Kit of the Company’s flagship immunoSEQ® platform technology. The launch of the immunoSEQ Kit is a breakthrough event for researchers of any immune-mediated disease, including cancer, autoimmune disorders, and infectious diseases, who are seeking highly quantitative and reliable measurements of T-cell Receptor Beta (TCRB) repertoires.
New York, NY – Adaptive Biotechnologies, a clinical stage diagnostics company that leverages Next Generation Sequencing (NGS) to profile the adaptive immune system, announced today that Chad Robins, its Founder and Chief Executive Officer, is speaking on a panel discussion titled “How is Personalized Medicine Guiding Drug Development in 2014?”
BOSTON, MA – Adaptive Biotechnologies CEO Chad Robins joins distinguished panel at Cancer Advance Conference at Harvard Medical School. In the panel, “Next Generation – Omics Technologies: Innovation in Rx/Dx Strategies,” Mr. Robins will elucidate how Adaptive’s assays are being incorporated into clinical trials in hematologic malignancies and solid tumors.
Adaptive Biotechnologies, a clinical stage diagnostics company that leverages Next Generation Sequencing to profile the adaptive immune system, announced today that it has established a Scientific Advisory Board to provide strategic and clinical guidance for the implementation of its clinical diagnostic suite of assays in the diagnosis and monitoring of patients with leukemia and lymphoma. The initial focus of the SAB will be to support the utility of clonoSEQ, Adaptive’s highly accurate and sensitive NGS assay for monitoring Minimal Residual Disease (MRD) in patients with blood cancer.
Adaptive was featured in the recent issue of Seattle Business under the headline: Adaptive Biotechnologies’ ‘Tools of the Trade’. Local firm takes a huge step forward in helping scientists understand the complexities of the human immune system.
SEATTLE, September 16, 2014 (PR NEWSWIRE) – Adaptive Biotechnologies, a clinical stage diagnostics company that leverages Next Generation Sequencing (NGS) to profile the adaptive immune system, is pleased to announce the appointment of Brian Hansen as Chief Commercial Officer (CCO). The addition of Brian to the Company’s expanding Executive Leadership Team follows recent key hires from leading global healthcare companies, including Dean Schorno (CFO) and Kathleen Determann (General Counsel) from Genomic Health and Sean Nolan (CTO) from Microsoft’s Healthvault.
Adaptive CEO Chad Robins will deliver a speech today at the Center for Commercialization (C4C) at the University of Washington titled “The Story of Adaptive Biotechnologies.”
Adaptive announced today that Chad Robins, its Founder and Chief Executive Officer, is participating in a panel discussion this morning at the prestigious Genomics 2.0 Conference in Park City, Utah. The panel, entitled “Changing the Game in Oncology,” includes other industry notables Randy Scott, CEO of Invitae, Steven Kafka, COO of Foundation Medicine, and Ronnie Andrews, Division President at Thermo Fisher.